Strategic Leadership Enhancements at Sibylla Biotech
In an exciting development for Sibylla Biotech, the company has bolstered its leadership team with two noteworthy appointments. Stefan Ries joins as Chief Scientific Officer (CSO), bringing over two decades of rich experience in drug development from the pharmaceutical industry and a solid foundation in venture capital. Additionally, Elena Ardini steps in as Vice President of Research and Development (R&D), boasting more than 20 years in oncology drug discovery and a commendable history of advancing innovative therapies towards clinical evaluation.
New Appointments to Drive Innovation
Both Stefan and Elena are poised to leverage their extensive knowledge of drug discovery to propel Sibylla’s pipeline forward. Their appointments are crucial in transitioning the company’s Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology into preclinical and clinical development stages.
As noted by Lidia Pieri, PhD, MBA, Co-Founder and Chief Executive Officer of Sibylla Biotech, the addition of Stefan and Elena will significantly strengthen the company’s scientific leadership. "Their dedication to pioneering therapeutics coupled with a sharp business acumen and expertise in corporate strategy will be vital as we explore new therapeutic avenues using our innovative technology," she said.
Stefan Ries: A Visionary in Drug Development
Stefan Ries brings a depth of experience as a scientific executive, particularly focusing on oncology. His prior role as CSO of DISCO Pharmaceuticals allowed him to lead R&D strategies and scalable drug discovery activities successfully. Furthermore, his time as a Venture Partner at Versant Ventures showcases his commitment to supporting novel therapeutic advancements.
Having spent 16 years at Hoffmann-La Roche, Stefan culminated his tenure as Vice President of External Innovation in Oncology, overseeing scientific due diligence for collaboration and asset evaluation. He holds a PhD in Biochemistry from the University of Regensburg, Germany, and completed a postdoctoral fellowship at the University of California, San Francisco, where he worked under the renowned Professor Frank McCormick. An active member of the American Association for Cancer Research, Stefan is well-equipped to lead Sibylla’s innovative pursuits.
Elena Ardini: Expertise in Oncology Drug Discovery
Elena Ardini’s illustrious career in cancer research is marked by her versatility in drug discovery and development. Having held various positions since 2000 at Nerviano Medical Sciences, she brings invaluable insights in the development of small molecule oncology drugs. Her recent role as Asset Leader and Clinical Project Leader attests to her leadership capabilities.
One of her notable achievements includes leading the pre-clinical development of entrectinib (Rozlytrek®), an important targeted therapy for solid tumors. Elena’s academic foundation is equally impressive, holding a master's degree in Biological Sciences from the University of Milano, Italy. Her excitement about joining Sibylla centers around leveraging advanced technology to transform the treatment landscape for patients with critical needs.
Innovative Therapeutic Approaches at Sibylla Biotech
Sibylla Biotech is on a mission to revolutionize drug discovery by focusing on protein folding intermediates. This innovative strategy unlocks a new pharmacological domain, targeting proteins early in their folding process before they become difficult to drug. Through its proprietary PPI-FIT technology, Sibylla aims to disrupt conventional drug discovery frameworks, providing a fresh perspective on tackling hard-to-treat diseases.
By predicting intermediate steps in protein folding, Sibylla’s small molecule candidates can induce targeted protein degradation through physiological pathways. This pioneering approach is geared towards addressing unmet medical needs across various therapeutic areas, demonstrating Sibylla’s commitment to improving patient outcomes globally.
Company Commitment to Advancing Healthcare Solutions
Sibylla is dedicated to advancing a diverse pipeline of therapeutic solutions that cater to significant healthcare challenges. With a strong scientific leadership team now in place, the company is well-positioned to make substantial progress in the application of its PPI-FIT technology.
The organization’s focus on delivering innovative therapeutics to patients worldwide underscores its mission to expand possibilities in drug discovery, ultimately aiming to bring relief to those with limited treatment options.
Frequently Asked Questions
What roles have been newly appointed at Sibylla Biotech?
Stefan Ries has been appointed Chief Scientific Officer, and Elena Ardini has taken on the role of Vice President of Research and Development.
What experience does Stefan Ries bring to Sibylla Biotech?
Stefan brings over 20 years of experience in drug discovery and development, with a strong emphasis on oncology and venture capital insights.
What is Elena Ardini's background in drug development?
Elena has over 20 years of experience in oncology drug discovery and has been involved in developing innovative therapies, including pre-clinical evaluations of important cancer treatments.
What innovative technology does Sibylla Biotech utilize?
Sibylla uses a proprietary technology platform known as PPI-FIT, which targets protein folding intermediates, providing new pathways for drug development.
How does Sibylla Biotech approach drug discovery?
By focusing on early intervention in the protein folding process, Sibylla seeks to develop drugs that can address previously undruggable targets, enhancing therapeutic options for patients.
